This site is intended for healthcare professionals
News

Bimzelx is approved in Japan for the treatment of plaque psoriasis, generalized pustular psoriasis and psoriatic erythroderma.

Read time: 1 mins
Published:24th Jan 2022
UCB announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing authorization for Bimezlx (bimekizumab) for the treatment of plaque psoriasis, generalized pustular psoriasis and psoriatic erythroderma in patients who are not sufficiently responding to existing treatments.

Bimekizumab is the first approved psoriasis treatment in Japan that is designed to selectively and directly inhibit two key cytokines driving inflammatory processes – interleukin 17F (IL-17F) and interleukin 17A (IL-17A).

This announcement marks the third approval for bimekizumab worldwide, following marketing authorization in countries of the European Union/European Economic Area and Great Britain in August 2021 for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Condition: Psoriasis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.